Nanjing Pharmaceutical Co (SHSE:600713) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600713 Nanjing Pharmaceutical Co Ltd SHSE:600713
63 GF Score
Price ¥5.08
GF Value ¥4.64
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Nanjing Pharmaceutical Co Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nanjing Pharmaceutical Co  (SHSE:600713) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nanjing Pharmaceutical Co Cyclically Adjusted PB Ratio Related Terms


Nanjing Pharmaceutical Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Nanjing Pharmaceutical Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Pharmaceutical Co Cyclically Adjusted PB Ratio Chart

Nanjing Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 1.27 1.11 1.06 1.09

Nanjing Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 1.04 1.12 1.07 1.00

SHSE:600713 vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Nanjing Pharmaceutical Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing Pharmaceutical Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing Pharmaceutical Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nanjing Pharmaceutical Co's Cyclically Adjusted PB Ratio falls into.


SHSE:600713
63GF Score
Nanjing Pharmaceutical Co Ltd SHSE:600713
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Pharmaceutical Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nanjing Pharmaceutical Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Nanjing Pharmaceutical Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.342/116.0564*116.0564
=6.342

Current CPI (Jun. 2026) = 116.0564.

Nanjing Pharmaceutical Co Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.142 102.400 3.561
201612 3.420 102.600 3.869
201703 3.503 103.200 3.939
201706 3.526 103.100 3.969
201709 3.459 104.100 3.856
201712 3.551 104.500 3.944
201803 4.021 105.300 4.432
201806 4.045 104.900 4.475
201809 4.088 106.600 4.451
201812 3.945 106.500 4.299
201903 4.017 107.700 4.329
201906 4.064 107.700 4.379
201909 4.190 109.800 4.429
201912 4.339 111.200 4.528
202003 4.445 112.300 4.594
202006 4.427 110.400 4.654
202009 4.555 111.700 4.733
202012 4.628 111.500 4.817
202103 4.728 112.662 4.870
202106 4.755 111.769 4.937
202109 4.826 112.215 4.991
202112 5.025 113.108 5.156
202203 4.926 114.335 5.000
202206 4.957 114.558 5.022
202209 5.053 115.339 5.084
202212 5.180 115.116 5.222
202303 5.342 115.116 5.386
202306 5.371 114.558 5.441
202309 5.468 115.339 5.502
202312 5.614 114.781 5.676
202403 5.746 115.227 5.787
202406 5.693 114.781 5.756
202409 5.816 115.785 5.830
202412 5.970 114.893 6.030
202503 6.145 115.116 6.195
202506 6.101 114.907 6.162
202509 6.182 115.471 6.213
202512 6.300 115.832 6.312
202603 6.466 116.303 6.452
202606 6.342 116.056 6.342

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Nanjing Pharmaceutical Co (SHSE:600713) Overvalued in 2026?

Based on GuruFocus' analysis, Nanjing Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.08 is trading 9.5% above its estimated GF Value™ of ¥4.64. GuruFocus considers Nanjing Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600713:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ¥4.64 vs. price of ¥5.08 (9.5% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600713 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanjing Pharmaceutical Co Business Description

Address No. 55, Andemen Street, Building 2, Yuhuatai District, Jiangsu Province, Nanjing, CHN, 210002
Nanjing Pharmaceutical Co Ltd is engaged in the pharmaceutical service business.
63GF Score

Get the complete analysis for SHSE:600713

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.08
Price
¥4.64
GF Value